compounded semaglutide crackdown news november 2025 Important Update: Changes to Availability Novo abruptly ends obesity drug

doi: 10.7812/TPP/21.204

Piotrowski K, Becker M, Zugwurst J, Biller-Friedmann I, Spoettl G, Greif M, Leber AW, Becker A, Laubender RP, Lebherz C, Goeke B, Marx N, Parhofer KG, Lehrke M: Circulating concentrations of GLP-1 are associated with coronary atherosclerosis in humans

Some GLP-1s (e.g., Zepbound) are being studied or already approved for non-weight-loss uses like this

The right medication depends on your health history, insurance plan, diagnosis, availability, and provider review

The consistency of response was equally remarkable

29, 2024 /PRNewswire/ -- Smoothie King, the world's leading smoothie brand, is proud to announce the launch of its GLP-1 Support Menu for guests using GLP-1 agonists to help them achieve their weight loss or weight management goals